Search clinical trials for: AIDS vaccines

Total 7905 results

AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB

Tuberculosis, Pulmonary
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; University of Oxford

Recruiting

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

HIV-1-infection

United States, Brazil
Makerere University
MRC/UVRI and LSHTM Uganda Research Unit; Ministry of Health, Uganda; Epicentre; Makerere University Lung Institute and other collaborators

Not yet recruiting

Solidarity/Tokomeza Ebola Trial (TOKOMEZA)

Sudan Ebola Virus Vaccines
International Maternal Pediatric Adolescent AIDS...
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaborators

Not yet recruiting

Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

HIV Infections | Tuberculosis

South Africa
Madhu Chhanda Choudhary
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy (NETI)

HIV Infections

United States
National Center for Disease control and Public...
World Health Organization

Recruiting

COVID-19 Vaccine Effectiveness Among Health Workers in Georgia (COV19HWVE_GE)

Covid19

Georgia
VA Eastern Colorado Health Care System

Recruiting

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

HIV Infections | HIV/AIDS | Human Immunodeficiency Virus | HIV-1-infection

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

COVID-19 Prevention

United States, Germany, Brazil, Poland, South Africa
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19

United States, United Kingdom, Belgium, Spain, France, Germany, Philippines, Brazil, Colombia, South Africa
Henry M. Jackson Foundation for the Advancement...
US Military HIV Research Program; Janssen Vaccines & Prevention B.V.

Withdrawn

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission (RV582)

HIV-1-infection

Thailand
International AIDS Vaccine Initiative
Emory University; Fred Hutchinson Cancer Center; George Washington University; ModernaTX... and other collaborators

Active, not recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Hiv

United States
Pfizer

Completed

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Influenza, Human

United States, Brazil, South Africa, Philippines, New Zealand, Chile, Argentina
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI); University of Copenhagen; US... and other collaborators

Completed

Vaccination for Recovered Inpatients With COVID-19 (VATICO)

Covid19

United States, Spain, Uganda, Nigeria, Singapore, Switzerland
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC; Inovio Pharmaceuticals

Active, not recruiting

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

Anal Intraepithelial Neoplasia | High Grade Squamous Intraepithelial Neoplasia | HIV Positivity | Human Papillomavirus-16 Positive | Human Papillomavirus-18 Positive

United States, Puerto Rico
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Evandro Chagas National Institute of Infectious... and other collaborators

Active, not recruiting

Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial (OPTIMO)

HIV Infection

Peru, Brazil, Haiti
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol

United States, Mexico, South Africa, Brazil, Chile, Colombia, Peru, Argentina
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of California, Los Angeles; Merck... and other collaborators

Active, not recruiting

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV (COVENANT)

HIV Infection | AIDS-Related Human Papillomavirus Infection | High Grade Cervical Squamous Intraepithelial Neoplasia

Uganda, Kenya, Zimbabwe, South Africa, Malawi
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

Infection | Precancerous Condition

United States
MRC/UVRI and LSHTM Uganda Research Unit
King's College London; Karolinska Institutet; Gilead Sciences; Imperial College... and other collaborators

Enrolling by invitation

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (PrEPVacc)

HIV Infections

Uganda
Janssen Vaccines & Prevention B.V.

Completed

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (MOSAICO)

Healthy

United States, Mexico, Spain, Puerto Rico, Italy, Poland, Argentina, Brazil, Peru
ANRS, Emerging Infectious Diseases
University College London Hospitals; Hospital Clinic of Barcelona; Imperial College... and other collaborators

Completed

A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)

HIV-1-infection

France, United Kingdom, Switzerland
Aelix Therapeutics
Gilead Sciences

Completed

Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients (AELIX-003)

HIV/AIDS

Spain
Janssen Vaccines & Prevention B.V.
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaborators

Completed

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

Healthy

United States, South Africa, Thailand, Uganda, Rwanda
National Institute of Allergy and Infectious Diseases...
Fred Hutchinson Cancer Center; International AIDS Vaccine Initiative; HIV Vaccine... and other collaborators

Active, not recruiting

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

Covid19 | SARS-CoV2 Infection

United States
Janssen Vaccines & Prevention B.V.

Terminated

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

HIV-1

South Africa, Malawi, Mozambique, Zambia, Zimbabwe
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

HIV Infections

United States, Peru
Albert B. Sabin Vaccine Institute
ICON plc; Oklahoma Blood Institute

Completed

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

Ebola Virus Disease | Marburg Virus Disease

United States
Epividian
AIDS Healthcare Foundation

Completed

COVID-19 Quantitative Antibody Titers & Booster Vaccinations

COVID-19 | COVID-19 Vaccines | Immunogenicity, Vaccine

United States
University of Oxford
Imperial College London; KEMRI-Wellcome Trust Collaborative Research Program; University of Nairobi and other collaborators

Active, not recruiting

A Study to Test Three Experimental HIV Vaccines in Healthy Adults. (HIV-CORE 006)

HIV-1-infection

Kenya, Uganda, Zambia
International AIDS Vaccine Initiative
GlaxoSmithKline; George Washington University; Amsterdam UMC, location VUmc; Rockefeller...

Active, not recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

HIV Infections

United States, Netherlands
National Institute of Allergy and Infectious Diseases...

Completed

HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Bill and Melinda Gates Foundation; Medical Research Council; Sanofi... and other collaborators

Completed

A Safety and Immune Response Study of 2 Experimental HIV Vaccines

HIV Infection

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Pasteur Merieux Connaught

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen

HIV Infections

United States

Search clinical trials for: AIDS vaccines

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations